Rare NRG1 Fusion Market to Grow Positively at a Paltry CAGR During the Study Period, Assesses DelveInsight | Elevation Oncology, Merus, Hummingbird Bioscience, Boehringer Ingelheim, AVEO Oncology and CANbridge Pharmaceuticals, Salubris Biotherapeutics

DelveInsight's "Rare NRG1 Fusion - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Rare NRG1 Fusion market share of the individual therapies, current and forecasted Rare NRG1 Fusion market size from 2020 to 2034 segmented by seven major markets. The report also offers current Rare NRG1 Fusion therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Rare NRG1 Fusion market.
Download report @ https://www.delveinsight.com/report-store/rare-nrg1-fusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the Rare NRG1 Fusion Market Report:
As of 2024, there are no approved targeted therapies specifically for NRG1 fusions. The standard treatment for advanced tumors with NRG1 fusions continues to be chemotherapy and/or immunotherapy, including novel anti-PD-1 or anti-PD-L1 agents. The market for rare NRG1 fusions is anticipated to grow significantly due to the anticipated launch and rapid adoption of upcoming tumor-agnostic therapies, an expected increase in the testing rate for NRG1 gene fusions in clinical practice, ongoing research and development efforts, and the repurposing of existing drugs alongside advancements in precision medicine.
NRG1 fusions are a rare condition, occurring in approximately 0.2% of solid tumors across various types, with the exception of IMA, which accounts for 2%-10% of lung adenocarcinomas. The total number of incident cases of rare NRG1 fusions in the seven major markets (7MM) was around 5,800 in 2023. The total market size for NRG1 fusions in the 7MM was approximately USD 37 million in 2023 and is projected to increase during the forecast period from 2024 to 2034.
Companies developing treatments for NRG1 fusions can benefit from orphan drug designations, which offer advantages such as 7 years of market exclusivity in the US, subsidies for clinical trials, reduced regulatory fees, and other benefits. Additionally, they can also receive fast track designation and priority review, which can expedite the approval process and reduce development costs and time.

Rare NRG1 Fusion Overview
NRG1 (Neuregulin 1) gene fusions are potentially targetable oncogenic drivers found in certain solid tumors. These fusions lead to the activation of ErbB-mediated pathways, presenting a logical therapeutic target. Oncogenic NRG1 fusions can result in an excessive accumulation of the NRG1-fusion protein on the cell surface, causing persistent activation of ErbB receptor tyrosine kinases. This, in turn, drives excessive activity in the mTOR and MAPK pathways, promoting tumorigenesis. The NRG1 gene encodes ligands for the ERBB2 (HER2)-ERBB3 heterodimeric receptor tyrosine kinase. Various NRG1 gene fusions, such as CD74-NRG1 and SLC33A2-NRG1, have been identified at low frequencies across a broad spectrum of carcinomas, including lung, breast, colorectal, ovarian, and pancreatic cancers, with a variety of fusion partners.
Rare NRG1 Fusion Epidemiological Insights
In 2021, there were a total of 5,733 incident cases of rare NRG1 fusions in the seven major markets (7MM), and this number is expected to grow over the study period from 2020 to 2034.
Rare NRG1 Fusion Treatment Market
NRG1 fusions have been detected in more than 10 types of solid tumors, which makes them a promising candidate for a tumor-agnostic therapeutic development approach. The growing awareness, research, and development in this area are creating a favorable environment for key players in the pharmaceutical industry. Several ERBB3 inhibitors with promising preclinical data are currently undergoing various stages of clinical trials, some of which are being tested in combination with ERBB2-targeting drugs in ERBB2-positive tumors of the breast and stomach.

Among the emerging players, Merus's zenocutuzumab is at the forefront, with data presented at ASCO 2022 indicating its potential to become the first approved drug for NRG1 fusions. The drug has shown durable responses in previously treated NRG1 fusion-positive cancers, with a median duration of response exceeding 9 months. Seribantumab, another contender, and other potential drugs under study have a slightly different mechanism, requiring binding to both HER2 and HER3, rather than just HER3. Ongoing studies are exploring which mechanism-binding to HER3 alone or to both HER2 and HER3-is more effective.

Several companies are actively involved in initiating clinical trials to explore new treatment options or to optimize the use of existing treatments. Key players include Elevation Oncology (Seribantumab), Merus (Zenocutuzumab), AVEO Oncology (AV-203), Hummingbird Bioscience (HMBD-001), and others, all of whom are investigating their candidates for the management of rare NRG1 fusions.
To know more about Rare NRG1 Fusion Treatment Market, request for our sample report @ https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Rare NRG1 Fusion Market Insights:
In 2023, the total market size for NRG1 Fusion in the United States was approximately USD 22 million, with projections indicating growth throughout the forecast period from 2024 to 2034.
Among the EU4 countries, Germany led the market size for NRG1 Fusion in 2023, while Spain had the smallest market share.
In terms of therapy revenue, current and off-label therapies generated the highest revenue for NRG1 Fusion in the United States in 2023.
Promising Therapies in the Rare NRG1 Fusion Pipeline
MM-121/Seribantumab
Zenocutuzumab/MCLA-128
HMBD-001
And others
Discover more about Rare NRG1 Fusion therapies in the pipeline @ https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Rare NRG1 Fusion Market
Elevation Oncology
Merus
Hummingbird Bioscience
And others
To understand key companies related to the Rare NRG1 Fusion Market, get a snapshot of the Rare NRG1 Fusion Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Rare NRG1 Fusion Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Rare NRG1 Fusion Companies: Elevation Oncology, Merus, Hummingbird Bioscience, and others
Key Rare NRG1 Fusion Pipeline Therapies: MM-121/Seribantumab, Zenocutuzumab/MCLA-128, HMBD-001, and others
Therapeutic Assessment: Rare NRG1 Fusion current marketed and emerging therapies
Rare NRG1 Fusion Market Dynamics: Rare NRG1 Fusion market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Rare NRG1 Fusion Market Access and Reimbursement
Table of Contents
1. Rare NRG1 Fusion Market Key Insights
2. Rare NRG1 Fusion Market Report Introduction
3. Rare NRG1 Fusion Market Overview at a Glance
4. Rare NRG1 Fusion Market Executive Summary
5. Disease Background and Overview
6. Rare NRG1 Fusion Treatment and Management
7. Rare NRG1 Fusion Epidemiology and Patient Population
8. Patient Journey
9. Rare NRG1 Fusion Emerging Drugs
10. 7MM Rare NRG1 Fusion Market Analysis
11. Rare NRG1 Fusion Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Rare NRG1 Fusion Market Drivers
15. Rare NRG1 Fusion Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports by DelveInsight:

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight:

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.